Real-world data from an ongoing international audit of testosterone deficiency in men with type 2 diabetes, which was  presented at the 2023 Annual Meeting of The European Association for the Study of Diabetes (EASD), suggests that testosterone replacement therapy (TRT) improves glycaemic control for up to two years.

The early data from 37 centres across eight countries who have so far joined the Association of British Clinical Diabetologists (ABCD) audit, suggest that the reason HbA1c continues to decrease over time is likely to be due to the ongoing effect of testosterone on insulin resistance and fat reduction. The results provide preliminary insights into the controversial question of whether TRT could have a beneficial effect on diabetes and obesity.

Two decades ago, researchers discovered a link between low testosterone in men and the prevalence of type 2 diabetes. Estimates suggest that around 40% of men with type 2 diabetes have symptomatic testosterone deficiency. Testosterone deficiency is linked with adverse effects on cardiovascular risk factors, osteoporosis, and psychological wellbeing, and is associated with double the risk of death in men with type 2 diabetes.

Multiple studies have shown that TRT could have benefits for men with hypogonadism (testosterone deficiency) who also have type 2 diabetes, obesity, and other cardiometabolic disorders. TRT has been shown to reduce insulin resistance, HbA1c, cholesterol, obesity, and mortality, and improve quality of life, and sexual function.

However, uptake of TRT has been slow in practice in part due to conflicting findings on cardiovascular risks. However, a multi-centre randomised trial, recently published in the NEJM, on the cardiovascular safety of TRT  found no difference in major cardiovascular events between testosterone and placebo-treated groups.

The ABCD audit allows anonymised data input from new and retrospective patients who have commenced on TRT and also those with testosterone deficiency who are not treated. 

The aim of the audit is to determine the real-world benefits and safety of TRT on symptoms, glycaemic control, obesity, other cardiometabolic parameters (eg. lipids, blood pressure, BMI and waist circumference) and on cardiovascular events and diabetes complications.

In total, 34 centres in eight countries (the UK, Germany, Canada, New Zealand, Brazil, South Africa, Malaysia and Vietnam) including 428 patients (average age 71 years) have so far joined the audit. The testosterone formulations used by these patients are gels and long-acting testosterone undecanoate intramuscular injections. Testosterone guidelines state that after initiation of TRT patients should be reviewed at three, six, and 12 months and then yearly from then on.

The researchers evaluated HbA1c on paired data after three, 12 and 24 months on patients included in the audit treated with TRT. The recommended range for most people with diabetes is to keep HbA1c under 48mmol/mol.

After three months of treatment with TRT, average HbA1c fell by 4.9mmol/mol from 71mmol/mol to 66mmol/mol (81 patients); after 12 months average HbA1c fell by 9.6mmol/mol from 71mmol/mol to 61.7mmol/mol (121 patients); and after 24 months it declined by 15.4mmol/mol from 71.2mmol/mol to 55mmol/mol (101 patients).